These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 33786278

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C.
    J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
    [Abstract] [Full Text] [Related]

  • 5. A case of rapidly progressive insulin-dependent diabetes mellitus without islet autoantibodies developed over two years after the first dose of nivolumab.
    Nishihama K, Okano Y, Inoue C, Maki K, Eguchi K, Tanaka S, Takeshita A, Uemura M, Yasuma T, Suzuki T, Gabazza EC, Yano Y.
    Diabetol Int; 2024 Jul; 15(3):583-588. PubMed ID: 39101192
    [Abstract] [Full Text] [Related]

  • 6. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
    Yaura K, Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z.
    Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic mucosal melanoma.
    Goff CB, Plaxe SC, White W, Dasanu CA.
    J Oncol Pharm Pract; 2023 Jul; 29(5):1259-1263. PubMed ID: 36734125
    [Abstract] [Full Text] [Related]

  • 9. High titre of antiglutamic acid decarboxylase autoantibody is a strong predictor of the development of thyroid autoimmunity in patients with type 1 diabetes and latent autoimmune diabetes in adults.
    Jin P, Huang G, Lin J, Yang L, Xiang B, Zhou W, Zhou Z.
    Clin Endocrinol (Oxf); 2011 May; 74(5):587-92. PubMed ID: 21470281
    [Abstract] [Full Text] [Related]

  • 10. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L, Zou X, Chen Y, Bai X, Liang T.
    Front Immunol; 2020 May; 11():2076. PubMed ID: 32973816
    [Abstract] [Full Text] [Related]

  • 11. Genetic heterogeneity of autoimmune diabetes: age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43). UK Prospective Diabetes Study (UKPDS) Group.
    Horton V, Stratton I, Bottazzo GF, Shattock M, Mackay I, Zimmet P, Manley S, Holman R, Turner R.
    Diabetologia; 1999 May; 42(5):608-16. PubMed ID: 10333055
    [Abstract] [Full Text] [Related]

  • 12. Trends in endogenous insulin secretion capacity and anti-islet autoantibody titers in two childhood-onset slowly progressive insulin-dependent diabetes mellitus cases.
    Suzuki D, Shima H, Kawashima S, Kamimura M, Kikuchi A, Kanno J.
    Clin Pediatr Endocrinol; 2024 Oct; 33(4):238-243. PubMed ID: 39359664
    [Abstract] [Full Text] [Related]

  • 13. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
    Ohara N, Kobayashi M, Ohashi K, Ito R, Ikeda Y, Kawaguchi G, Yoneoka Y, Hasegawa G, Takada T.
    J Med Case Rep; 2019 Mar 26; 13(1):88. PubMed ID: 30909965
    [Abstract] [Full Text] [Related]

  • 14. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
    Thapi S, Leiter A, Galsky M, Gallagher EJ.
    J Immunother Cancer; 2019 Sep 12; 7(1):248. PubMed ID: 31511065
    [Abstract] [Full Text] [Related]

  • 15. Checking the Checkpoint Inhibitors: A Case of Autoimmune Diabetes After PD-1 Inhibition in a Patient with HIV.
    Hughes MS, Pietropaolo M, Vasudevan MM, Marcelli M, Nguyen H.
    J Endocr Soc; 2020 Dec 01; 4(12):bvaa150. PubMed ID: 33225197
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.
    Iyer PC, Cabanillas ME, Waguespack SG, Hu MI, Thosani S, Lavis VR, Busaidy NL, Subudhi SK, Diab A, Dadu R.
    Thyroid; 2018 Oct 01; 28(10):1243-1251. PubMed ID: 30132401
    [Abstract] [Full Text] [Related]

  • 18. Immune checkpoint inhibitor-related type 1 diabetes mellitus which develops long after treatment discontinuation: a case report and review of literature.
    Obata Y, Takemoto M, Sakaue TA, Kawata S, Mukai K, Miyashita K, Kozawa J, Nishizawa H, Shimomura I.
    Diabetol Int; 2024 Jul 01; 15(3):605-610. PubMed ID: 39101180
    [Abstract] [Full Text] [Related]

  • 19. [Latent autoimmune diabetes in adults(LADA): part of the clinical spectrum of type-1 diabetes mellitus of autoimmune origin].
    Pánczél P, Hosszúfalusi N, Bornemisza B, Horváth L, Jánoskuti L, Füst G, Rajczy K, Vatay A, Prohászka Z, Madácsy L, Luczay A, Blatniczky L, Halmos T, Körner A, Szilvási I, Romics L.
    Orv Hetil; 2001 Nov 18; 142(46):2571-8. PubMed ID: 11770176
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.